ID

25020

Descrizione

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence; ODM derived from: https://clinicaltrials.gov/show/NCT00480623

collegamento

https://clinicaltrials.gov/show/NCT00480623

Keywords

versioni (1)
  1. 24/08/17 24/08/17 -
Caricato su

24 agosto 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Prostate Cancer NCT00480623

Inglese

Eligibility Prostate Cancer NCT00480623

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
over or equal to 18 years of age.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
ecog performance status less than or equal to 1
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
adequate organ function.
Descrizione

Organ function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0678852
history of radical prostatectomy with histopathologic documentation of adenocarcinoma of the prostate.
Descrizione

Radical prostatectomy | Adenocarcinoma of prostate

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0194810
UMLS CUI [2]
C0007112
psa over or equal to 0.2 ng/ml or less than or equal to 0.4 ng/ml. this includes patients whose psa never becomes detectable. psa progression must be measured by two consecutive samples, each separated by over or equal to 7 days. the psa values of the two consecutive sample values must be greater than the previous (baseline) value, not greater than each other.
Descrizione

PSA measurement | PSA Undetectable | PSA Progression Sample Consecutive Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201544
UMLS CUI [2,1]
C0138741
UMLS CUI [2,2]
C3827727
UMLS CUI [3,1]
C4054264
UMLS CUI [3,2]
C0370003
UMLS CUI [3,3]
C1707491
UMLS CUI [3,4]
C1265611
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
known sites of measurable prostate cancer or bone scan positive for metastatic prostate cancer. (patients with a positive prostascint scan will not be excluded)
Descrizione

Site Known Prostate carcinoma Measurable | Secondary malignant neoplasm of prostate Bone scan Positive | ProstaScint Scan Positive allowed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1515974
UMLS CUI [1,2]
C0205309
UMLS CUI [1,3]
C0600139
UMLS CUI [1,4]
C1513040
UMLS CUI [2,1]
C0347001
UMLS CUI [2,2]
C0203668
UMLS CUI [2,3]
C1514241
UMLS CUI [3,1]
C2985362
UMLS CUI [3,2]
C1514241
UMLS CUI [3,3]
C0683607
prior therapy for prostate cancer except rp and neoadjuvant hormonal therapy. this includes chemo, hormonal (except neoadjuvant), rt, and biologic therapy.
Descrizione

Therapeutic procedure Prostate carcinoma | Exception Radical prostatectomy | Exception Hormone Therapy Neoadjuvant | Chemotherapy | Hormone Therapy | Therapeutic radiology procedure | Biological treatment

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0600139
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0194810
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0279025
UMLS CUI [3,3]
C0600558
UMLS CUI [4]
C0392920
UMLS CUI [5]
C0279025
UMLS CUI [6]
C1522449
UMLS CUI [7]
C1531518
lack of physical integrity of the upper gi tract, malabsorption syndromes, or inability to tolerate or absorb oral medications, including crohn's disease and ulcerative colitis.
Descrizione

Upper gastrointestinal tract Integrity Lacking | Malabsorption Syndrome | Intolerance to oral medication | Oral medication Intake Unable | Crohn Disease | Ulcerative Colitis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1268997
UMLS CUI [1,2]
C1947912
UMLS CUI [1,3]
C0332268
UMLS CUI [2]
C0024523
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C0175795
UMLS CUI [4,1]
C0175795
UMLS CUI [4,2]
C1512806
UMLS CUI [4,3]
C1299582
UMLS CUI [5]
C0010346
UMLS CUI [6]
C0009324
other concurrent immunotherapy, rt, chemotherapy,or ancillary therapy considered investigational (utilized for non-fda approved indications and the context of a research investigation)and any chemotherapy not included in the study protocol.
Descrizione

Immunotherapy Investigational | Therapeutic radiology procedure Investigational | Chemotherapy Investigational | Therapeutic procedure Ancillary Investigational

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021083
UMLS CUI [1,2]
C1517586
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C1517586
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C1517586
UMLS CUI [4,1]
C0087111
UMLS CUI [4,2]
C1549485
UMLS CUI [4,3]
C1517586
Ritorna all'inizio della pagina

Similar models

Eligibility Prostate Cancer NCT00480623

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
over or equal to 18 years of age.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status less than or equal to 1
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
adequate organ function.
boolean
C0678852 (UMLS CUI [1])
Radical prostatectomy | Adenocarcinoma of prostate
Item
history of radical prostatectomy with histopathologic documentation of adenocarcinoma of the prostate.
boolean
C0194810 (UMLS CUI [1])
C0007112 (UMLS CUI [2])
PSA measurement | PSA Undetectable | PSA Progression Sample Consecutive Quantity
Item
psa over or equal to 0.2 ng/ml or less than or equal to 0.4 ng/ml. this includes patients whose psa never becomes detectable. psa progression must be measured by two consecutive samples, each separated by over or equal to 7 days. the psa values of the two consecutive sample values must be greater than the previous (baseline) value, not greater than each other.
boolean
C0201544 (UMLS CUI [1])
C0138741 (UMLS CUI [2,1])
C3827727 (UMLS CUI [2,2])
C4054264 (UMLS CUI [3,1])
C0370003 (UMLS CUI [3,2])
C1707491 (UMLS CUI [3,3])
C1265611 (UMLS CUI [3,4])
Item Group
C0680251 (UMLS CUI)
Site Known Prostate carcinoma Measurable | Secondary malignant neoplasm of prostate Bone scan Positive | ProstaScint Scan Positive allowed
Item
known sites of measurable prostate cancer or bone scan positive for metastatic prostate cancer. (patients with a positive prostascint scan will not be excluded)
boolean
C1515974 (UMLS CUI [1,1])
C0205309 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C1513040 (UMLS CUI [1,4])
C0347001 (UMLS CUI [2,1])
C0203668 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
C2985362 (UMLS CUI [3,1])
C1514241 (UMLS CUI [3,2])
C0683607 (UMLS CUI [3,3])
Therapeutic procedure Prostate carcinoma | Exception Radical prostatectomy | Exception Hormone Therapy Neoadjuvant | Chemotherapy | Hormone Therapy | Therapeutic radiology procedure | Biological treatment
Item
prior therapy for prostate cancer except rp and neoadjuvant hormonal therapy. this includes chemo, hormonal (except neoadjuvant), rt, and biologic therapy.
boolean
C0087111 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0194810 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0279025 (UMLS CUI [3,2])
C0600558 (UMLS CUI [3,3])
C0392920 (UMLS CUI [4])
C0279025 (UMLS CUI [5])
C1522449 (UMLS CUI [6])
C1531518 (UMLS CUI [7])
Upper gastrointestinal tract Integrity Lacking | Malabsorption Syndrome | Intolerance to oral medication | Oral medication Intake Unable | Crohn Disease | Ulcerative Colitis
Item
lack of physical integrity of the upper gi tract, malabsorption syndromes, or inability to tolerate or absorb oral medications, including crohn's disease and ulcerative colitis.
boolean
C1268997 (UMLS CUI [1,1])
C1947912 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
C0024523 (UMLS CUI [2])
C1744706 (UMLS CUI [3,1])
C0175795 (UMLS CUI [3,2])
C0175795 (UMLS CUI [4,1])
C1512806 (UMLS CUI [4,2])
C1299582 (UMLS CUI [4,3])
C0010346 (UMLS CUI [5])
C0009324 (UMLS CUI [6])
Immunotherapy Investigational | Therapeutic radiology procedure Investigational | Chemotherapy Investigational | Therapeutic procedure Ancillary Investigational
Item
other concurrent immunotherapy, rt, chemotherapy,or ancillary therapy considered investigational (utilized for non-fda approved indications and the context of a research investigation)and any chemotherapy not included in the study protocol.
boolean
C0021083 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3,1])
C1517586 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C1549485 (UMLS CUI [4,2])
C1517586 (UMLS CUI [4,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial